peel-224
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 11, 2022 (NCT05329103)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Topoisomerase IANTAGONIST
topoisomerase I
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06721689 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2025 | Peel Therapeutics Inc, University of Pennsylvania |
| NCT06709495 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2024 | Harvard University, Peel Therapeutics Inc |
| NCT05329103 | Phase 1 | Jul 11, 2022 | Peel Therapeutics Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peel Therapeutics Inc | For profit | 3 | 1 | 2 | 2022 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1